CAREDX, INC. vs GUARDANT HEALTH, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where CDNA and GH diverge most: on operating margin, CDNA reads 1.0% and GH reads -40.2%; on fcf yield, CDNA reads 3.3% and GH reads -1.2%. The rest of the comparable metrics sit closer together. What GH's price implies is a somewhat stretched bet versus history (revenue-multiple basis). The bull and bear cases for each are in their full reports below.
| Metric | CDNA | GH |
|---|---|---|
| Price | $39.73 | $155.89 |
| Market cap | $2.1B | $20.5B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/B | 6.73 | — |
| P/S | 5.11 | 18.94 |
| Revenue growth | +19.7% | +39.3% |
| Operating margin | 1.0% | -40.2% |
| Net margin | -2.0% | -40.1% |
| Return on equity | -2.6% | — |
| Return on assets | -2.0% | -22.6% |
| Return on invested capital | -4.1% | -26.7% |
| FCF yield | 3.3% | -1.2% |
| Debt / equity | 0.00 | — |
| Current ratio | 3.40 | 4.68 |
| Altman Z (solvency) | 5.07 | 4.61 |
| Piotroski F (quality) | 6 / 9 | 3 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.